Overview

Exploratory Study to Evaluate an Occlusion Based Dentifrice in Relief of Dentinal Hypersensitivity

Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this exploratory study is to compare the treatment effect on dentinal hypersensitivity of a tubule occluding dentifrice as measured by Schiff and Tactile sensitivity. This proof of concept study will compare the test dentifrice with three other treatment groups.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
GlaxoSmithKline
Collaborator:
BioSci Research
Treatments:
Calcium
Calcium, Dietary
Fluorides
Fluorophosphate
Listerine
Sodium Fluoride
Criteria
Inclusion Criteria:

1. Participants between 18 and 55 years of age, in good general health, with pre-existing
self-reported and clinically diagnosed tooth sensitivity are required for entry into
the study

2. Participants will be required to have at least four teeth with facial/cervical
erosion, abrasion and/or gingival recession which respond to qualifying evaporative
(air) assessment at the Screening visit and have at least two teeth (incisors, canines
or pre-molars) demonstrating signs of sensitivity, measured by qualifying tactile
threshold (Yeaple ≤ 20 gram (g)) and evaporative (air) (Schiff Sensitivity Score ≥ 2)
assessments at the Baseline visit

Exclusion Criteria:

1. Pregnancy: Women who are known to be pregnant or who are intending to become pregnant
over the duration of the study.

2. Breast-feeding: Women who are breast-feeding.

3. Medical History: a) Chronic debilitating disease is present b) Chronic disease or
other condition is present that is associated with intermittent episodes or constant
daily pain, such as arthritis, low back pain, dysmenorrhea, etc.

4. Medications: Daily doses of medication, which in the opinion of the investigator,
might interfere with the perception of pain, are being taken. Examples of such
medications include analgesics, anticonvulsants, antihistamines that cause marked or
moderate sedation, sedatives, tranquilizers, mood-altering and anti-inflammatory
drugs.

5. Dentition Exclusions: a) Sensitive teeth not expected to respond to treatment with an
over-the- counter dentifrice in the opinion of the investigator. b) Teeth with exposed
dentine but with deep, defective or facial restorations, teeth used as abutments for
fixed or removable partial dentures, teeth with full crowns, orthodontic bands,
extensive caries or cracked enamel. Sensitive teeth with contributing etiologies other
than erosion, abrasion or recession of exposed dentine. c) Dental professional hygiene
(includes dental prophylaxis, irrigation, and intensive anti-microbial/anti-biotic
therapy) within 14 days of the screening visit. d) Presence of dental implants. e) Lip
or tongue piercings. f) Periodontal surgical history within the past 6 months or have
been scaled /root planed within the past 3 months.

6. Allergy/Intolerance: Known or suspected intolerance or hypersensitivity to the study
materials (or closely related compounds) or any of their stated ingredients.

7. Clinical Study/Experimental Medication: a) Participation in another clinical study or
receipt of an investigational drug within 30 days of the screening visit b) Previous
participation in this study.

8. Other: Any subject who in the opinion of the investigator, should not participate in
the study.